Organic compositions to treat APOC3-related diseases

• US 10,240,153 B2
• Filed: 01/11/2017
• Issued: 03/26/2019
• Est. Priority Date: 07/16/2014
• Status: Active Grant

• Current Assignee: Arrowhead Pharmaceuticals, Inc.
• Original Assignee: Arrowhead Pharmaceuticals, Inc.
• Inventors: Weiler, Jan, Chutkow, William, Baryza, Jeremy Lee, Krueger, Andrew, Zhao, Junping
• Primary Examiner(s): Vivlemore, Tracy
• Application Number:
  US15/403,919
• Publication Number:
  US 20170137814A1
• Time in Patent Office: 804 Days
• Field of Search: None
• CPC Class Codes: A61K 31/713 Double-stranded nucleic acids or oligonucleotides
• CPC Class Codes: C07H 21/02 with ribosyl as saccharide radical
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/322 2'-R Modification
• CPC Class Codes: C12N 2310/341 Gapmers, i.e. of the type ===---===
• CPC Class Codes: C12N 2310/344 Position-specific modifications, e.g. on every purine, at the 3'-end
• CPC Class Codes: C12N 2310/351 Conjugate
• CPC Class Codes: C12N 2310/3515 Lipophilic moiety, e.g. cholesterol
• CPC Class Codes: C12N 2310/3521 Methyl
• CPC Class Codes: C12N 2310/3525 MOE, methoxyethoxy
• CPC Class Codes: C12N 2310/3533 Halogen
• CPC Class Codes: C12N 2320/31 Combination therapy

Abstract

The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.

Claims

1. A double-stranded RNAi agent for inhibiting expression of an APOC3 gene in a cell, the RNAi anent comprising a first strand and a second strand, wherein said first strand is less than about 49 nucleotides in length and comprises at least 19 contiguous nucleotides differing by 0 or 1 nucleotides from the nucleotide sequence (5′

to 3′

) AGCACUGAGAAUACUGUCC (SEQ ID NO;

     132), wherein the second strand is substantially complementary to the first strand, wherein the first strand comprises at least one modified nucleotide or modified internucleoside linkage, wherein the 3′

end of the first strand and/or the second strand comprises a 3′

end cap, and wherein the 3′

end of the first and/or second strand terminates in a phosphate or modified internucleoside linker and further comprises, in 5′

to 3′

order;

a spacer, a second phosphate or modified internucleoside linker, and a 3′

end cap.

2. The RNAi agent of claim 1, wherein the spacer is selected from a sugar, alkyl, cycloalkyl, ribitol, 2′

-deoxy-ribitol, diribitol, 2′

-methoxyethoxy-ribitol, C3 [—

(CH₂)₃—

], C4 [—

(CH₂)₄—

], C5 [—

(CH₂)₅—

], C6 [—

(CH₂)₆—

], or 4-methoxybutane-1,3-diol.

3. The RNAi agent of claim 1, wherein the RNAi agent is ligated to one or more diagnostic compound, reporter group, cross-linking agent, nuclease-resistance conferring moiety, natural or unusual nucleobase, lipophilic molecule, cholesterol, lipid, lectin, steroid, uvaol, hecigenin, diosgenin, terpene, triterpene, sarsasapogenin, Friedelin, epifriedelanol-derivatized lithocholic acid, vitamin, carbohydrate, dextran, pullulan, chitin, chitosan, synthetic carbohydrate, oligo lactate 15-mer, natural polymer, low- or medium-molecular weight polymer, inulin, cyclodextrin, hyaluronic acid, protein, protein-binding agent, integrin-targeting molecule, polycationic, peptide, polyamine, peptide mimic, and/or transferrin.

4. The RNAi agent of claim 1, wherein the RNAi agent is ligated to one or more carbohydrates.

5. The RNAi agent of claim 1, wherein the RNAi agent is ligated to one or more N-Acetylgalactosamines.

7. The RNAi agent of claim 1, wherein the 3′

end cap comprises;

8. A pharmaceutical composition comprising one or more RNAi agents of claim 1, and at least one pharmaceutically acceptable excipient.

9. A cell or vector containing the RNAi agent of claim 1.

10. The RNAi agent of claim 1, wherein the second strand is less than about 49 nucleotides in length and comprises at least 19 contiguous nucleotides differing by 0, or 1 nucleotides from the nucleotide sequence (5′

to 3′

) GACAGUAUUCUCAGUGCUU (SEQ ID NO;

     71).

11. The RNAi agent of claim 10, wherein the first strand and second strand comprise the duplex pair of SEQ ID NOs:

378/290;

484/438;

485/438;

486/438;

487/438;

488/438;

489/438;

490/438;

491/438;

492/438;

493/438;

494/438;

495/438;

496/438;

497/438;

498/438;

499/438;

500/438;

501/438;

502/438;

or 503/439.

6. A double-stranded RNAi agent for inhibiting expression of an APOC3 gene in a cell, the RNAi agent comprising a first strand and a second strand, wherein said first strand is less than about 49 nucleotides in length and comprises at least 19 continuous nucleotides differing by 0 or 1 nucleotides from the nucleotide sequence (5′

to 3′

) AGCACUGAGAAUACUGUCC (SEQ ID NO;

     132), and wherein the second strand is substantially complementary to the first strand, wherein the RNAi agent is ligated to an N-Acctylgalactosamine-containing compound that comprises the following structure;

16. A pharmaceutical composition comprising one or more RNAi agents of claim 6, and at least one pharmaceutically acceptable excipient.

12. A double-stranded RNAi agent for inhibiting expression of an APOC3 gene in a cell, the RNAi agent comprising a first strand and a second strand wherein the first strand and second strand comprise the duplex pair of SEQ ID NOs:

484/438, 485/438, 486/438;

487/438;

488/438;

489/438;

491/438;

496/438;

497/438;

498/438;

499/438;

501/438;

502/438;

or 503/439.

13. The RNAi agent of claim 12, wherein the 3′

end of the first strand and/or the second strand comprises a 3′

end cap.

14. The RNAi agent of claim 12, wherein the first strand and the second strand form a duplex region of about 15 to about 30 nucleotide base pairs.

15. The RNAi agent of claim 12, wherein one or more nucleotides of the first strand or the second strand has been replaced by a spacer.

17. A pharmaceutical composition comprising one or more RNAi agents of claim 12, and at least one pharmaceutically acceptable excipient.